Picoplatin

Picoplatin

Names
IUPAC name azane; 2-methylpyridine; platinum(2+); dichloride
Identifiers
CAS Number	181630-15-9
ChemSpider	154428
Jmol 3D model	Interactive image
PubChem	177358
UNII	B5TAN0L720
InChI InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 Key: IIMIOEBMYPRQGU-UHFFFAOYSA-L InChI=1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 Key: IIMIOEBMYPRQGU-NUQVWONBAG
SMILES Cc1ccccn1.N.[Cl-].[Cl-].[Pt+2]
Properties
Chemical formula	C6H10Cl2N2Pt
Molar mass	376.14 g·mol^−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is  ?)
Infobox references

Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.^[1]

In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.^[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.^[3] Hopes are now pinned on its use for metastatic colorectal cancer.^[4]

References

1. The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Transactions
2. Picoplatin Clinical Results, Poniard Pharmaceuticals
3. Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
4. http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009